PMID- 32901315
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1573-7322 (Electronic)
IS  - 1382-4147 (Print)
IS  - 1382-4147 (Linking)
VI  - 26
IP  - 2
DP  - 2021 Mar
TI  - Renal protection: a leading mechanism for cardiovascular benefit in patients 
      treated with SGLT2 inhibitors.
PG  - 337-345
LID - 10.1007/s10741-020-10024-2 [doi]
AB  - Initially developed as glucose-lowering drugs, sodium-glucose co-transporter type 
      2 inhibitors (SGLT2i) have demonstrated to be effective agents for the risk 
      reduction of cardiovascular (CV) events in patients with type 2 diabetes mellitus 
      (T2DM). Subsequently, data has emerged showing a significant CV benefit in 
      patients treated with SGLT2i regardless of diabetes status. Renal protection has 
      been initially evaluated in CV randomized trials only as secondary endpoints; 
      nonetheless, the positive results gained have rapidly led to the evaluation of 
      nephroprotection as primary outcome in the CREDENCE trial. Different renal and 
      vascular mechanisms can account for the CV and renal benefits enlightened in 
      recent literature. As clinical guidelines rapidly evolve and the role of SGLT2i 
      appears to become pivotal for CV, T2DM, and kidney disease management, in this 
      review, we analyze the renal effects of SGLT2, the benefits derived from its 
      inhibition, and how this may result in the multiple CV and renal benefits 
      evidenced in recent clinical trials.
FAU - Margonato, Davide
AU  - Margonato D
AUID- ORCID: 0000-0002-5817-6901
AD  - Heart Failure Unit and Department of Cardiology, Policlinico di Monza, Via Amati 
      111, 20900, Monza, Italy. dvdmrgnt@gmail.com.
AD  - Department of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 
      dvdmrgnt@gmail.com.
FAU - Galati, Giuseppe
AU  - Galati G
AD  - Heart Failure Unit and Department of Cardiology, San Raffaele Hospital and 
      Scientific Institute (IRCCS), Milan, Italy.
FAU - Mazzetti, Simone
AU  - Mazzetti S
AD  - Heart Failure Unit and Department of Cardiology, Policlinico di Monza, Via Amati 
      111, 20900, Monza, Italy.
FAU - Cannistraci, Rosa
AU  - Cannistraci R
AD  - Department of Medicine and Surgery, Universita Degli Studi di Milano Bicocca, & 
      Policlinico di Monza, Monza, Italy.
FAU - Perseghin, Gianluca
AU  - Perseghin G
AD  - Department of Medicine and Surgery, Universita Degli Studi di Milano Bicocca, & 
      Policlinico di Monza, Monza, Italy.
FAU - Margonato, Alberto
AU  - Margonato A
AD  - Heart Failure Unit and Department of Cardiology, San Raffaele Hospital and 
      Scientific Institute (IRCCS), Milan, Italy.
FAU - Mortara, Andrea
AU  - Mortara A
AD  - Heart Failure Unit and Department of Cardiology, Policlinico di Monza, Via Amati 
      111, 20900, Monza, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200908
PL  - United States
TA  - Heart Fail Rev
JT  - Heart failure reviews
JID - 9612481
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - *Cardiovascular Diseases/prevention & control
MH  - *Cardiovascular System
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Humans
MH  - Kidney
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
PMC - PMC7895775
OTO - NOTNLM
OT  - Cardiovascular outcomes
OT  - Chronic kidney disease
OT  - Heart failure
OT  - Renal protection
OT  - SGLT2 inhibitors
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/09/10 06:00
MHDA- 2021/12/15 06:00
PMCR- 2020/09/08
CRDT- 2020/09/09 05:31
PHST- 2020/08/31 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/09/09 05:31 [entrez]
PHST- 2020/09/08 00:00 [pmc-release]
AID - 10.1007/s10741-020-10024-2 [pii]
AID - 10024 [pii]
AID - 10.1007/s10741-020-10024-2 [doi]
PST - ppublish
SO  - Heart Fail Rev. 2021 Mar;26(2):337-345. doi: 10.1007/s10741-020-10024-2. Epub 
      2020 Sep 8.